

Haematologica
HAEMATOL/2017/186304
Version 3

Long-term management of leukocyte adhesion deficiency type III
without hematopoietic stem cell transplantation

Paul Saultier, Sarah Szepetowski, Matthias Canault, Céline Falaise,
Marjorie Poggi, Pierre Suchon, Vincent Barlogis, Gérard Michel,
Stéphane Loyau, Martine Jandrot-Perrus, Jean-Claude Bordet,
Marie-Christine Alessi, and Hervé Chambost

Disclosures: 1) The study was funded by the Fondation pour la Recherche Médicale (grant to PSA: FDM20150633607). The authors thank Laurence Panicot-Dubois and Christophe Dubois (Aix-Marseille Univ, INSERM, VRCM, Marseille, France) for the kind gift of Gly-Pro-Arg-Pro, David Gabriele for technical assistance, Sandra Moore for the revision of the paper, and the patient and his family for the participation in this study. 2) PSa has received support for attending scientific meetings and educational events from Baxalta-Shire, Novo Nordisk, and Pfizer. HC has received support for attending scientific meetings and honoraria (speaker fees/consultant on advisory boards) from Baxalta-Shire, Bayer Healthcare, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer and Sobi; has been an investigator in studies sponsored by Baxter, Bayer, Biogen, CSL Behring, LFB and Octapharma; and has received research support from CSL Behring, LFB, Novo Nordisk and Octapharma (none of these relate to the present study). CF has received support for attending scientific meetings and honoraria (speaker fees/consultant on advisory boards) from Baxalta-Shire, CSL Behring, LFB, Pfizer and Sobi; has been an investigator in studies sponsored by Baxter, Bayer, Biogen, CSL Behring, LFB and Octapharma; and has received research support from CSL Behring, LFB, Novo Nordisk and Octapharma (none of these relate to the present study). The other authors have no conflict of interest to disclose. All these companies had no role in the study design, the collection or interpretation of the data, the preparation of the manuscript and the decision to submit it for publication. 3) NA

Contributions: PSa designed and performed the systematic review of the literature, designed and performed the in vitro experiments, and wrote the paper. SS performed the systematic review of the literature, analyzed data, and wrote the paper. MC designed the in vitro experiments, analyzed the data, and revised the paper. CF provided clinical data and revised the paper. MP and PSu participated in the in vitro experiments, analyzed the data and revised the paper. VB and GM analyzed the data and revised the paper. SL and MJP provided the anti-GPVI antibody, analyzed the data, and revised the paper. JCB performed the electron microscopy study, analyzed the data, and revised the paper. MCA designed the in vitro experiments, analyzed the data and wrote the paper. HC designed and supervised the research and wrote the paper.